ARCHIVES

CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely

This article is from The Cancer Letter archive.

Vol. 29 No. 21 | May 23, 2003

Download PDF Visit The Full Archive

Related Articles

Final Issue Of ‘77

December 16, 1977

NCI Advisory Group, Other Cancer Meeting

May 26, 1978

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990

Philadelphia Firm Wins CIDAC Award

August 24, 1984

Conference On Delayed Consequences Of Cancer Therapy Scheduled Jan. 9-11

January 3, 1975

Judge Hears Arguments In Fisher’s Privacy Act Suit Over Databases

January 19, 1996